Burning Rock Biotech Limited Sponsored ADR (BNR) reported its second quarter 2026 financial results. Quarterly financial results often trigger major shifts in stock price and investor outlook for the company.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | 1 | — | — | 1 | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | ‡‡‡‡‡ |
|
| 2025 | ‡‡‡‡‡ |
|
| 2024 | ‡‡‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 86.65 | 71.54 | 68.80 | 61.77 |
| Receivables | 17.87 | 20.83 | 24.25 | 25.46 |
| Inventory | 9.72 | 8.58 | 6.95 | 5.03 |
| Other | 3.20 | 1.90 | 2.96 | 2.27 |
| 124.52 | 106.40 | 105.62 | 97.87 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 2.54 | 4.62 | 5.83 | 2.65 |
| ST’ Debt | — | — | 0.03 | 0.03 |
| Other | 0.17 | 0.08 | 0.09 | 0.09 |
| 37.10 | 36.48 | 35.32 | 32.06 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 15.65 | 19.86 | — | — |
—
|
| ’25 | 18.34 | 20.74 | 18.49 | 19.59 |
77.16
|
| ’24 | 17.40 | 18.65 | 18.33 | 16.29 |
70.67
|
| ’23 | 20.75 | 20.17 | 17.49 | 17.29 |
75.70
|
| ’22 | 21.38 | 19.53 | 21.74 | 19.01 |
81.66
|
| ’21 | 16.27 | 19.71 | 19.65 | 24.06 |
79.69
|
| ’20 | 9.65 | 15.14 | 18.25 | 19.88 |
65.89
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.25) | (3.36) | — | — |
—
|
| ’25 | (3.24) | (6.23) | 2.24 | 3.16 |
(4.07)
|
| ’24 | (5.57) | (5.58) | (4.71) | 3.22 |
(12.64)
|
| ’23 | (16.47) | (10.05) | (6.34) | (3.16) |
(36.03)
|
| ’22 | (22.77) | (15.10) | (16.83) | (11.53) |
(66.23)
|
| ’21 | (17.27) | (18.68) | (20.78) | (18.26) |
(74.99)
|
| ’20 | (1.00) | 8.70 | 2.52 | (13.10) |
(11.27)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.25) | (3.36) | — | — |
—
|
| ’25 | (3.24) | (6.23) | 2.24 | 2.54 |
(4.70)
|
| ’24 | (5.57) | (5.58) | (4.71) | 2.62 |
(13.24)
|
| ’23 | (16.47) | (10.05) | (6.34) | (4.47) |
(37.33)
|
| ’22 | (22.77) | (21.50) | (16.83) | (21.40) |
(76.10)
|
| ’21 | (17.27) | (18.68) | (20.78) | (51.67) |
(108.40)
|
| ’20 | (1.00) | 8.70 | 2.52 | (13.10) |
(23.36)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.20) | (0.20) | — | — |
—
|
| ’25 | (0.17) | (0.15) | (0.26) | (0.21) |
(0.73)
|
| ’24 | (0.16) | (0.14) | (0.50) | (1.08) |
(4.61)
|
| ’23 | (2.60) | (1.80) | (2.30) | (2.20) |
(9.00)
|
| ’22 | (3.90) | (3.70) | (3.10) | (3.10) |
(13.60)
|
| ’21 | (2.50) | (3.00) | (2.50) | (3.80) |
(12.00)
|
| ’20 | (0.11) | (3.80) | (1.80) | (0.23) |
(10.50)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡ | 17.00 | 6.89 | 2.62 | 2.18 | — | — | — |
Low Price
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 112.70 | 38.00 | 9.99 | 24.18 | — | — | — |
High Price
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,138 | 786 | 674 | 667 | — | — | — |
Employees
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.07 | 0.10 | 0.10 | 0.12 | — | — | — |
Revenue/Emp
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 81.66 | 75.70 | 70.67 | 77.16 | ‡‡‡‡‡ | — | — |
Revenue
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 67.47% | 67.58% | 70.25% | 74.67% | — | — | — |
Gross Margin
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (140.53) | (91.73) | (46.68) | (7.69) | — | — | — |
EBT
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (172.08%) | (121.19%) | (66.06%) | (9.97%) | ‡‡‡ | — | — |
EBT Margin
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (140.81) | (92.07) | (47.49) | (7.92) | ‡‡‡‡‡ | — | — |
Net Income
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.99 | 18.79 | 7.15 | 3.11 | — | — | — |
Depreciation
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.86 | 7.39 | 6.87 | 7.26 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.60) | (9.00) | (4.61) | (0.73) | ‡‡‡‡‡ | — | — |
Earnings/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (6.37) | (3.52) | (1.23) | (0.38) | ‡‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.95) | (0.13) | (0.06) | (0.06) | ‡‡‡‡‡ | — | — |
Capex/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.32) | (3.65) | (1.29) | (0.44) | — | — | — |
Free CF/Sh
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.16 | 10.57 | 7.73 | 7.20 | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.39 | 10.24 | 10.29 | 10.63 | ‡‡‡‡‡ | — | — |
Shares
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡ | — | — |
PE Ratio
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.75 | 1.31 | 0.98 | 2.78 | ‡‡‡ | — | — |
PS Ratio
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.34 | 0.92 | 0.87 | 2.80 | ‡‡‡ | — | — |
PB Ratio
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.20 | 0.20 | 0.01 | 1.89 | ‡‡‡‡ | — | — |
EV/Sales
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.47) | (0.17) | (0.02) | (8.83) | — | — | — |
EV/FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (66.23) | (36.03) | (12.64) | (4.07) | ‡‡‡‡‡ | — | — |
Op' Cash Flow
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (9.87) | (1.31) | (0.60) | (0.63) | ‡‡‡‡‡ | — | — |
Capex
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (76.10) | (37.33) | (13.24) | (4.70) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 122.85 | 87.43 | 69.91 | 70.30 | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.31 | — | — | 0.27 | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (126.85) | (86.65) | (71.54) | (68.52) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 167.94 | 108.23 | 79.57 | 76.54 | — | — | — |
Sh' Equity
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (47.92%) | (48.89%) | (35.47%) | (6.64%) | — | — | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (216.16%) | (273.06%) | (380.90%) | (61.14%) | — | — | — |
ROIC
|
| — | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (61.56%) | (66.68%) | (50.57%) | (10.14%) | — | — | — |
ROE
|
Burning Rock Biotech Limited (BNR), a leader in China’s precision oncology diagnostics via next-generation sequencing, rode explosive growth from $16 million revenue in 2017 to a $82 million peak in 2022 (38% CAGR), fueled by COVID-era testing demand, before a 13% contraction to $71 million in 2024 amid regulatory crackdowns, trade tensions, and cost cuts slashing headcount 36%. Despite persistent losses and a 97% stock plunge post-IPO, efficiency soared—revenue per employee doubled to $105,000, gross margins hit 70%, and a $715 million cash hoard offers a decade-long runway, trading at ultra-deep value (EV/Sales 0.008x).
Analyst forecasts ignite hypergrowth: 2025 revenue exploding 34x to $2.5 billion, flipping EPS positive at $0.71, with FCF at $98 million and consensus targets implying 1,720% upside—positioning BNR at attractive forward multiples versus biotech peers. Recent 190% stock rebound hints at catalysts like partnerships or acquisitions, decoupling from macro headwinds.
Yet risks loom—execution on 35x revenue jumps (15% historical hit rate), China regulations, and dilution from tripling shares—balanced by 72% modeled odds of doubling in 12 months. A high-conviction speculative buy for 300-500% potential.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.